AER Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty. Sheehan
This article was originally published in The Tan Sheet
Executive Summary
The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a recent Food & Drug Law Institute meeting in Washington, D.C